Focus groups reveal positive attitudes towards pharmacogenetics for antidepressant guidance in youth, suggesting improved treatment pathways.
Key Points
Participants viewed pharmacogenetics testing as a means to reduce the trial-and-error approach in antidepressant treatment, enhancing medication efficacy.
Concerns about the cost and accessibility of pharmacogenetics testing were prominent, potentially limiting its clinical implementation for youth.
Semi-structured interviews with 17 participants aged 18–24 highlighted key themes around treatment views and barriers to pharmacogenetics integration.
Education and awareness are crucial for both patients and providers to support the adoption of pharmacogenetics in youth psychiatric care.